Our Story

Noven – 1987 to Today

Noven's history began in 1987 in Miami, Florida, with the mission to develop differentiated prescription transdermal drug delivery systems (patches) to support patients across a range of therapeutic conditions. Today, Noven is the US platform for Hisamitsu, the world's largest patch manufacturer, with fully integrated R&D, clinical, manufacturing, and sales functions offering prescription products in the areas of women's health and mental health.

History

2023
June 2023
Launch of XELSTRYM® (dextroamphetamine) transdermal system, Cll
2022
March 2022
Approval of XELSTRYM®
2020
March 2020
Launch of SECUADO®
Secuado Boxes
2019
October 2019
SECUADO® (asenapine) transdermal system FDA approval
2016
June 2016
Brisdelle® (paroxetine) and Pexeva® (paroxetine) acquired by Sebela Pharmaceuticals
2015
February 2015
Minivelle® (Estradiol Transdermal System) 0.025 Mg/Day Dose Available By Prescription In U.S. Pharmacies. UPDATE: MINIVELLE has been removed from Market. ESTRADIOL TS, the authorized generic to MINIVELLE is available.
2013
November 2013
Launch of Brisdelle®
June 2013
Brisdelle® approved by the FDA
January 2013
Noven Women's Health team launches Minivelle®
2012
December 2012
Noven acquires Minivelle®, establishes Women's Health sales team
October 2012
Minivelle® approved by FDA
February 2011
Noven's Northeast operations consolidated in Empire State Building co-headquarters
2010
February 2010
Noven reacquires Daytrana® (methylphenidate transdermal system) from Shire. UPDATE: DAYTRANA has been removed from market. Methylphenidate TS, the authorized generic to DAYTRANA is available.
February 2010
Hisamitsu Carlsbad facility integrated with Noven operations
2009
February 2009
Noven acquired by Hisamitsu Pharmaceuticals; public company status concludes
February 2007
Noven acquires JDS Pharmaceuticals, expanding its portfolio and sales capabilities
2006
February 2006
Shire and Noven launch Daytrana®
2003
February 2003
Shire licenses Noven's Daytrana® patch for ADHD
1999
February 1999
Launch of Vivelle-Dot® (estradiol transdermal system), the world's smallest estrogen patch at the time
1998
February 1998
Launch of CombiPatch® (estradiol/norethindrone acetate transdermal system), the first combination (two-drug) patch

Fast Facts

Core Business:
Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.

Year of Incorporation:
1987

Employees:
Over 300

Board Member & Chief Executive Officer:
Takeshi Masumoto

Media, General Business
& Other Inquiries:
CorporateAffairs@noven.com

Partnering and Other Business Development Opportunities
Tel: 551-233-2700
BusDev@noven.com

Employment Inquiries:
Marilyn Reynaldo
Associate Director –
Talent Acquisition
mreynaldo@noven.com

Community Support:
Corporate Social Responsibility

Affiliated Companies:
Noven is a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. – bringing the benefits of patch therapy to patients around the world.

Noven's commercialized products are marketed and sold through Noven Therapeutics, LLC.

Grove Pharmaceuticals is the generic division of Noven Therapeutics, LLC.